Northwire Canada EditionSaturday, July 11, 2026
Northwire
GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0%
Earnings

Auxly Reports Fourth Quarter and Full Year 2025 Results

XLY · Price

Executive Summary

  • Auxly Cannabis Group reported FY 2025 net revenue of $151.5 M (+24% YoY) and Adjusted EBITDA of $43.8 M (+64% YoY), delivering a Material‑Positive earnings release.
  • Q4 2025 revenue reached $40.1 M (+16% YoY) with Adjusted EBITDA of $12.5 M, net income of $0.9 M and cash balance of $32.3 M; total debt to EBITDA improved to 1.1×.
  • Management announced a $10‑$12 M capital program for 2026 and disclosed that Auxly has become the DIP lender and stalking‑horse bidder for Ayurcann Inc.’s assets, indicating strategic M&A activity.

Key Details

  • FY 2025 Financial Highlights
  • Net revenue: $151.5 M (↑24%)
  • Gross Margin on Finished Cannabis Inventory Sold: 54% (↑8 pts)
  • Adjusted EBITDA: $43.8 M (↑64%) – margin 29%
  • Net income: $41.9 M (+356% YoY) → $0.03 per share
  • Cash & equivalents: $32.3 M (↑76% YoY)
  • Debt: $46.3 M (↓15% YoY); Debt/Adj‑EBITDA = 1.1×

  • Q4 2025 Financial Highlights

  • Net revenue: $40.1 M (↑16%)
  • Gross Margin on Finished Cannabis Inventory Sold: 56% (↑2 pts)
  • Adjusted EBITDA: $12.5 M (↑14%) – margin 31%
  • Net income: $0.9 M (+‑79% YoY due to fair‑value losses) → $0.001 per share
  • Cash at quarter end: $32.3 M

  • Operational Updates

  • Launched premium‑tier brand “South Point” in Alberta & Ontario.
  • Capital program for 2026: $10‑$12 M to upgrade Auxly Leamington facility and enable direct international shipments.

  • Strategic M&A Activity

  • Became DIP lender and stalking‑horse bidder for Ayurcann Inc.’s assets (vapes & pre‑rolls). Transaction size deemed conservative relative to cash position; aligns with growth strategy.

  • Outlook & Guidance

  • Continued focus on profitable growth in Canada, evaluating export opportunities, and allocating $10‑$12 M of operating cash flow to capital projects in 2026.

Notable Quotes

“Q4 2025 was a strong finish… we delivered 24% net revenue growth and 64% Adjusted EBITDA growth… Our balance sheet also strengthened materially… We are excited about the year ahead…” – Hugo Alves, CEO


All non‑material boilerplate, forward‑looking disclaimer text, and company background have been omitted.

Read the original news release →

More from AUXLY CANNABIS GROUP INC. J